Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH₂)D₃) and prostaglandin E₂ (PG

详细信息    查看全文

• 作者：Marc Thill ; Dorothea Fischer ; Katharina Kelling ; Friederike Hoellen ; Christine Dittmer ; Amadeus Hornemann ; Darius Salehin ; Klaus Diedrich ; Michael Friedrich ; Steffi Becker
• 关键词：Ovarian cancer ; Cyclooxygenase-2 ; 15-Hydroxyprostaglandin dehydrogenase ; Vitamin D receptor ; Prostaglandin E2 ; 25-Hydroxycholecalciferol
• 刊名：The Journal of Steroid Biochemistry and Molecular Biology
• 出版年：2010
• 出版时间：July 2010
• 年：2010
• 卷：121
• 期：1-2
• 页码：387-390
• 全文大小：275 K

文摘

Ovarian carcinomas are associated with increased inflammation which is based upon an up-regulation of inducible cyclooxygenase-2 (COX-2). Moreover, based on our previous published data, the extra-renal vitamin D metabolism seems to be dysregulated in comparison to healthy tissue. In order to gain further insight into the prostaglandin (PG)- and vitamin D-metabolism in ovarian carcinomas, the study aimed to evaluate the expression of the PG metabolising enzymes COX-2 and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) compared to the vitamin D receptor (VDR) in benign and malignant ovarian tissues. Additionally, we determined the 25-hydroxycholecalciferol (25(OH₂)D₃) serum levels. Expression of VDR, COX-2 and 15-PGDH was determined by Western blot analysis. Serum levels of 25(OH₂)D₃ and PGE₂ were measured by chemiluminescence-based and colorimetric immunoassay. We detected significantly higher expressions of the PG metabolising enzymes 15-PGDH and COX-2 in malignant tissue and PGE₂ serum levels were 2-fold higher in tumour patients. Furthermore, we found an inverse correlation to the VDR-expression which was 62.1 % lower in malignant tissues compared to that in benign tissues. Surprisingly, we could not detect any differences between the 25(OH₂)D₃ serum levels in either group (n = 20). These data suggest a correlation between PG- and vitamin D-metabolism in ovarian carcinomas.